Product Description
OTL-204 is a drug candidate from Orchard Therapeutics for the treatment of Neurometabolic/Neurodegenerative Disorders. (Sourced from: https://www.orchard-tx.com/approach/pipeline/)
Mechanisms of Action: Gene Therapy,Progranulin
Novel Mechanism: Yes
Modality: Gene Therapy
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Orchard Therapeutics
Company Location: LONDON X0 EC4N 6EU
Company CEO: Bobby Gaspar
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Dementia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|